• Home

    • Liver disease
    • Current therapies

  • The CARBALIVE project

    • Concept
    • New therapy
    • Research

  • Consortium Partners

  • News

    • Press Release

  • Publications

  • Co-ordinator contact

  • Members Pages

  • More

    Use tab to navigate through the menu items.
    Back

    Disclaimer as of 17 May 2022: The data relating to CARBALIVE described on the EC website should be considered a “preliminary analysis”’ and although it is based on a fully audited and monitored Clinical Study, the trial was terminated on March 26th 2020, due to the pandemic preventing patient travel to hospital for mandatory safety assessments. 31 of a possible 58 patients had been enrolled.  Further details on the CARBALIVE clinical study outcomes can be found on https://yaqrit.com/news/the-carbalive-consortium-announces-positive-results-of-a-phase-2-equivalent-trial-of-engineered-macroporous-carbons-as-a-novel-treatment-for-cirrhosis/ with details of the clinical study protocol on  the ClinicalTrials.gov web site  https://clinicaltrials.gov/ct2/show/record/NCT03202498. The results underwent QC review on February 14th 2022 and returned to the sponsor on April 15th 2022 to address any concerns raised. Once these have been addressed, the results will be made public and a copy of the Clinical Study Report will be available on request from the Sponsor: Yaqrit Limited (www.yaqrit.com)”

    • Twitter